Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, et al. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. J Clin Oncol 2022 Jul 22:JCO2101281. doi: 10.1200/JCO.21.01281.
PMID: 35867960